Nicole Lambert
@NicoleVLambert
Followers
31
Following
14
Media
2
Statuses
29
President, Myriad Genetic Laboratories
Park City, UT
Joined March 2012
Please join us for #PancChat next week as we discuss some of the recent news from #ASCO19 & other advances in #PancreaticCancer. Special guest @aakonc who just published an @ASCO guideline update will join us. Cc: @loconte @DrR_DUNNE @MPishvaian @BurrisSkip
Join us next week for #PancChat! We'll be chatting about "Advances in Pancreatic Cancer Research and Treatment" with co-hosts @drallysonocean @Aiims1742 @ShaalanBeg @NirajGusani @pancan and @lustgartenfdn on Tuesday, June 18th at 8pm EDT / 5pm PDT.
0
6
16
How do we protect vulnerable patients when there's a workforce shortage? Dr. Pascal Jean-Pierre explores a community-based model of medical education https://t.co/yosvpll2cg
#ASCOconnection
connection.asco.org
In a shortfall of oncology workers, already vulnerable patients in disadvantaged groups will suffer most. Dr. Pascal Jean-Pierre proposes strategic capacity building and examines the Florida State Uni
0
1
9
Shark Tank idea: a microwave that will self-destruct if someone tries to use it to cook fish.
366
2K
24K
Important news broke today for patients with pancreatic cancer. Watch more in this video with Myriad’s chief medical officer, Dr. Johnathan Lancaster. #ASCO19
0
7
6
Unprecedented time for our pancreatic patients at #ASCO19
NCCN Guidelines now recommend hereditary cancer genetic testing for all pancreatic cancers. This is a big reason why... #ASCO19 @MyriadMyRisk @myriadgenetics
0
0
5
Big day for pancreatic patients at #ASCO19
NCCN Guidelines now recommend hereditary cancer genetic testing for all pancreatic cancers. This is a big reason why... #ASCO19 @MyriadMyRisk @myriadgenetics
0
2
3
Happy to support patients and physicians who need to make fast treatment decisions #ASCO19
STAT: Faster Results for Patients with Pancreatic Cancer to Inform Treatment. https://t.co/82cW5MD6pR
#ASCO19
0
0
3
Mark your calendars for this breaking data at #ASCO19
0
0
1
BRCA testing for pancreatic cancer patients is already recommended by NCCN. Today's data on Olaparib give even more reason to identify all mutations. Stop by booth 5087 at #ASCO19 to find out how.
Myriad Genetics is committed to advancing personalized medicine and providing oncologists with high-quality genetic information to enhance care for their patients. Stop by booth 5087 at #ASCO19 to learn more.
1
6
9
Breaking news at #ASCO19
ICYMI, Myriad’s BRACAnalysis CDx® test identifies patients with metastatic pancreatic cancer who benefited from treatment with Lynparza®. Learn more: https://t.co/D09B34nawQ
#ASCO19
0
2
5
Dr Cliff Hudis, ASCO and CCF CEO announces 17 endowed Young Investigator Awards have been funded and will be given out this year! Helping brilliant young doctors get their careers started will ensure new breakthroughs for future cures.
0
1
2
Such hopeful news to wake up to at #ASCO19
Maintenance tx w PARP inhibitor olaparib delays progression of BRCA+ pancreatic cancer https://t.co/urjBRQdJah
#ASCO19 #pancsm #pancan
0
1
1
Another wonderful day at #ASCO19! My favorite part? 1:1 mentoring sessions and great convos with amazing women! Thanks to @ASCO for the opportunity to serve as a mentor! @NatashaDhawanMD and Dr. Lee - you inspire me! #WomenInMedicine #Mentorship @HemOncWomenDocs
2
12
57
While prostate cancer isn’t (yet) considered to be a Lynch syndrome-associated cancer in NCCN Guidelines, there is clearly a subset of men with prostate cancer attributed to Lynch syndrome. #ASCO19 @MyriadMyRisk @myriadgenetics
0
3
4
Very exciting news at #ASCO19 for men living with advanced prostate cancer
Dr Taplin discusses 3 important abstracts #ASCO19 - men with advanced #prostatecancer are clearly living longer today, but it’s not good enough! Olaparib may be an option in selected men, BRCA1/2 mutation carriers have the greatest benefit
0
2
2
Continued focus on evaluating the highest quality of molecular testing at #ASCO19
Come by Board 278 this morning to see our poster “Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.” Abstract 2634 #ASC019 @myriadgenetics @MyriadMyChoice
0
0
1
25+ years and still proud to be supporting cancer care at #ASCO19
Every day, the 2,900 employees at Myriad strive to be trusted advisors to our customers. https://t.co/7p4VI4KOSZ
#ASCO19 #Oncology #WeAreMyriad
0
1
5
Attending #ASCO19? Come visit booth 5087 to learn more about how personalized medicine can help you. @MyriadGenetics
0
5
6
Increasing advances for prostate cancer patients to receive targeted therapies based on mutation status just presented at #ASCO19
0
0
4
Love this quote at #ASCO19 from new ASCO ASCO President "When our Oncology providers are as diverse as possible and as diverse as all our patients are, we see the very best care."
0
4
11